GlassScriptPhysician profile
Mumtaz Mohidin
NPI 1689625253
$1,700.55
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,349 · 2020: $220 · 2021: $131.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $396.65 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $290.81 | 2019 | |
| Mannkind Corporation | $202.13 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $132.59 | 2019-2021 | |
| Abbvie INC. | $108.12 | 2019-2021 | |
| Abbott Laboratories | $85.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $79.10 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $76.46 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $58.55 | 2019-2020 | |
| Insulet Corporation | $57.47 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $48.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.19 | 2019 | |
| Lilly USA, LLC | $32.11 | 2021 | |
| Amarin Pharma, INC. | $26.05 | 2019 | |
| Corcept Therapeutics | $25.27 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.98 | 2019 | |
| Medtronic Minimed, INC. | $16.22 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mumtaz Mohidin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.